Skip to main content
. 2012 Apr 1;2012:803239. doi: 10.1155/2012/803239

Table 2.

Primary endpoints: Changes in the functional and symptom scales of EORTO-QLQ-C30 in the intent-to-treat population.

THL-P (n = 28) Placebo (n = 11) P-value
Change from baseline
EORTO-QLQ-C30
GHS/QOL 41.7 (29.2, 50.0) −33.3 (33.3, 0) <0.001*
Functional scales
 Physical 13.3 (3.3, 26.7) 0 (−13.3, 13.3) 0.014*
 Role 0 (0, 41.7) 0 (−16.7, 0) 0.018*
 Emotional 8.3 (0, 25.0) 0 (−33.3, 8.3) 0.024*
 Cognitive 16.7 (0, 16.7) 0 (−33.3, 0) <0.001*
 Social 0 (0, 33.3) 0 (−33.3, 33.3) 0.379
Symptom scales
 Fatigue −22.2 (−33.3, −11.1) 0 (−11.1, 22.2) <0.005*
 Nausea and vomiting 0 (0, 0) 0 (0, 16.7) 0.656
 Pain 0 (−25.0, 16.7) 0 (0, 16.7) 0.124
Single items
 Dyspnoea 0 (−33.3, 0) 0 (0, 0) 0.528
 Insomnia 0 (0, 16.7) 0 (0, 33.3) 0.569
 Appetite loss 0 (0, 0) 0 (0, 0) 0.633
 Constipation 0 (−16.7, 0) 0 (0, 0) 0.770
 Diarrhoea 0 (0, 33.3) 0 (0, 33.3) 0.866
 Financial difficulties 0 (0, 0) 0 (0, 0) 0.747

THL-P: Tien-Hsien liquid practical; EORTO-QLQ-C30: European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30.

*P < 0.05 versus placebo (Mann-Whitney U test). P < 0.05 versus baseline (Wilcoxon signed ranks test). Values are presented as median (interquartile).